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INTRODUCTION
Preeclampsia is a pregnancy specific disorder which complicates about
3-10% of all nulliparous gestation[1]. The incidence is markedly influenced by
race and ethnicity. Preeclampsia is the most common serious medical disorder
of human pregnancy. It is characterised by the  development of hypertension
with proteinuria after  20 weeks of  gestation .Edema is  no  longer  consider as
a diagnostic criteria  but it is commonly associated with the normal pregnancy.
The cause of Preeclampsia is not completely understood .various  assumption
based on  numerous  theories are being considered till date .
The etiology  of  preeclampsia is suggested to be abnormal placentation.
The disorder is usually manifested after 20th week of gestation and the
complications aggravate with the advancement of pregnancy and in the absence
of proper patient management. Fetal complications of preeclampsia are directly
related to gestational age and the severity of maternal  disease  and result in
increased rates of preterm delivery,  fetal growth restriction  (FGR), placental
abruption and perinatal death.
Homocysteine is a non protein sulphur containing amino acid . It is
similar to cysteine  and is derived as a result of conversion of  methionine .
Increased homocysteine levels in the blood causes endothelial cell dysfuntion
,activation  of  haemostasis , oxidative stress .Hyperhomocysteinemia has been
associated with pregnancy induced hypertension, abruption, vasculopathy,
recurrent pregnancy loss, still birth, deep vein thrombosis and neural tube
defects of the newborn.
Hyperhomocysteinemia leads to endothelial dysfunction through various
mechanisms. In addition to that homocysteine is also affect the fibrinolytic
pathway which is contributing  to the  pathophysiology  of preeclampsia.
In normal pregnancy, homocysteine levels are decreased than the non-
pregnant level[2], either due to hemodilution of pregnancy or the relative
deficiency due to increase in requirement by the mother and fetus .It has been
proposed that preeclampsia is associated with vascular damages are similar to
those associated with the hyperhomocysteinemia .Though many studies are
done elsewhere, studies on homocysteine in pregnancy are limited in South
India. Also there are limited studies correlating maternal homocysteine level
with the severity of preeclampsia This study is mainly aimed at finding the
association between maternal homocysteine level in preeclampsia and its
severity.
REVIEW OF LITERATURE
PREECLAMPSIA
Preeclampsia  is  a hypertensive  disorder of  pregnancy   associated
with  widespread vascular endothelial  malfunction, clinically  defined by
hypertension  and proteinuria occurring  after 20 weeks of pregnancy .
According  to  the new ACOG  diagnostic criteria for preeclampsia , the
diagnostic dependence on the proteinuria has been eliminated. The new  onset
of hypertension is associated  with absence of proteinuria and the presence of
thrombocytopenia, elevated  liver  enzymes, renal insufficiency, pulmonary
edema and cerebral  accident syndrome. Maternal disease due to preeclampsia
is hypertension and proteinuria with or without multisystem involvement. Fetal
disease due to preeclampsia includes are FGR, fetal hypoxia , oligohydramnios
[4,5].
DEFINITION OF PREECLAMPSIA:
The classical features of preeclampsia which includes hypertension,
proteinuria and edema. However, there is now universal agreement that edema
should not be considered as necessary to confirm the diagnosis of
preeclampsia , because edema is consider to  be common normal finding in
pregnancy  and  approximately one third of preeclamptic  women never
demonstrate edema.In general , preeclampsia is primarily defined as
hypertension occurring after 20 weeks of gestation together with proteinuria .
Hypertension in pregnancy is defined as
 Systolic blood pressure of 140mmHg or higher
 Diastolic blood pressure of 90mmHg or higher (Korotkoff V)
These measurements have to be confirmed on at least two occasions 4 to
6 hours apart.
The gold standard method for determining proteinuria is the 24-hour
urinary protein excretion.
Proteinuria is defined as
 Excretion of more than 300mg of protein/24hr
 Or a urinary protein-to-creatinine ratio of 30mg/mmol
 Or if the above methods are unavailable, a protein value of about
30mg/dl (≥ 1+ on dipstick ) 2 random urine samples collected 4 to 6 hr
apart.
 Urinary tract infection must  be excluded  before  attributing  the
proteinuria to  preeclampsia.
Dipstick testing   should  be used  only for screening purposes where
other methods are not available. In all pregnant women who present with
gestational hypertension the presence of proteinuria must be confirmed with a
protein-to- creatinine ratio[15,16] or preferably a 24-hour urine collection.
The new onset of hypertension  and  proteinuria after 20weeks gestation
are consider to be essential  criteria  to confirm the diagnosis of preeclampsia
in majority of healthy pregnant women. In about  10 to 15 % of women who
presents with HELLP syndrome  and in about 20 to 25% women who presents
directly with preeclampsia, either hypertension  or proteinuria is absent.
Therefore with acceptance of the fact that the disease progress and worsening
can occur in the absence of proteinuria. The Society of Obstetric Medicine of
Australia and New Zealand (SOMANZ) has widened these criteria and have
included the presence of other systemic manifestations irrespective of
presence and absence of   proteinuria .
SOCIETY OF OBSTETRIC MEDICINE OF AUSTRALIA AND
NEW ZEALAND DEFINITION OF PREECLAMPSIA
The onset of hypertension after 20weeks gestation is accompanied by
one or more of the following:
 Renal involvement:
o Proteinuria ≥ 300mg/24 hr or urine  spot  protein/creatinine ratio
≥ 30 mg/mmol
o Serum or plasma creatinine ≥ 0.09mmol/L or decreased urine output
( <500mL/24hr)
 Hematological involvement:
o Thrombocytopenia
o Disseminated intravascular coagulation
o Hemolysis
 Hepatic involvement:
o Abnormal liver function( SGOT and/or SGPT >50 IU/L, Elevated
serum bilirubin >25IU/L
o Upper abdomen pain
 Neurologic involvement:
o Convulsions(eclampsia)
o Hyperreflexia with sustained clonus
o Severe headache (persisting, atypical)
o Persistent visual disturbances (photopsia, scotomata, cortical
blindness, retinal vasospasm)
 Hemiparesis/ Hemiplegia
o Pulmonary edema
o FGR and signs of fetal distress
o Placental abruption
INCIDENCE AND RISK FACTORS:
Preeclampsia incidence is about   ranges 3  and  10  percent  [1,12] in a
healthy nulliparous women. In case of nulliparous women, preeclampsia occurs
in milder form. The onset of preeclampsia  in nulliparous women in near term
or intrapartum which accounts  for 75% of cases and such a occurrence has
minimal risk  of adverse outcomes. Whereas in case of women with a multiple
pregnancy,[24,25] chronic hypertension,[23,26] previous preeclampsia,[23,27]
pre gestational diabetes mellitus [23], and in those with pre existing
thrombophilias [28-30] preeclampsia occur in a very severe form.
Preeclampsia is considered as a disease occurring in primigravida
.Limited sperm exposure with the same partner prior to  conception[31-36]
increase the risk of  preeclampsia. There is a new factor in the recent days with
development in assisted reproductive technology has given way for multiple
challenges that affect the maternal  immune system thereby, accounting for
increased risk of  preeclampsia.
RISK FACTORS FOR PREECLAMPSIA
Couple related risk factors:
 Primi paternity and limited sperm exposure
 Pregnancy after artificial insemination
 Protective effect of partner change in case of previous preeclamptic
pregnancy
Maternal or pregnancy related risk factors:
 Advanced maternal age.
 Multiple pregnancy, previous history of preeclampsia
 Chronic hypertension and/or chronic renal disease.
 Maternal connective tissue disorders (e.g., SLE)
 Maternal chronic infections, maternal low birth weight
 Obesity and insulin resistance and pre gestational diabetes mellitus
 Previous history of thrombophilias, maternal susceptibility genes
 History of preeclampsia in the family, hydropic degeneration of
placenta
 Smoking( reduced risk)
Classification of hypertensive disorder of pregnancy
Gestational hypertension
It is defined as hypertension (BP 140/90) without proteinuria on at
least two occasions, at least 6hours apart after 20th weeks of gestation in
women known to be normotensive before pregnancy and before 20 weeks of
gestation. Characteristics of this condition that differentiates it from
preeclampsia is the absence of proteinuria and it is differentiated from chronic
hypertension by onset of problem after 20weeks and the absence of
hypertension before pregnancy. This condition  can be associated with maternal
obesity, multiple gestations, diabetes and previous history of preeclampsia.
This condition is not benign and pregnancy outcomes in severe gestational
hypertension is worse than in mild preeclampsia. The end result is about 15 to
20% patients with gestational hypertension  is development of  clinical
syndrome of preeclampsia . Early gestational hypertension might be associated
with preeclamptic pathology such as poor placentation and histologic evidence
of placental ischemia and hemodynamic changes characterised by
vasoconstriction and decreased cardiac output.
Early onset of gestational hypertension  has higher risk of developing
preeclampsia and morbidity. Gestational hypertension after  about 35 weeks or
near term is related to 10% risk of preeclampsia and a slight increase in risk of
adverse outcome and result in good perinatal outcome. There is strong
association of progression to preeclampsia for women with gestational
hypertension and a previous history of miscarriage and or low serum albumin
concentration. They have increased incidence of placental insufficiency, fetal
growth restriction, iatrogenic prematurity, admission to neo-natal intensive care
unit and placental abruption.
Diagnostic criteria of gestational hypertension:
1. Blood pressure ≥150/100mmhg
2. Gestational age less than 30weeks
3. Evidence of end organs damage increased serum creatinine,liver
enzymes, LDH, thromocytopenia
4. Oligohydramnios
5. FGR
6. Abnormal uterine artery and /or umbilical artery Doppler velocimetry
ETIOPATHOGENESIS OF PREECLAMPSIA
The exact etiology of preeclampsia is still unknown. Redmann, Sargent
and co-workers have proposed the two stage hypothesis for preeclampsia.
According to this model, stage 1 is caused by faulty endovascular trophoblastic
remodelling leading to poor placentation which causes the stage 2 clinical
syndrome due to placental oxidative stress and inflammation. Stage 1 occurs
in the first half of pregnancy and stage2 in the second half of pregnancy.
Such compartmentalization is arbitrary as preeclampsia is a
continuous process. Preeclampsia is more likely a continuum of
worsening disease.
VASCULAR ENDOTHELIAL ACTIVATION AND PRO AND
ANTIANGIOGENIC PROTEINS IN PREECLAMPSIA:
The endothelium is one of the key cells involved in the pathophysiology
of preeclampsia which leads to an imbalance between the prostacyclin and
thromboxane [40-42] and impairment of nitric oxide synthesis, a potent
vasodilator. Endothelial cell activation leads to platelet activation and this
activated platelets cause thrombosis of the spiral arteries which in turn causes a
decreased uteroplacental blood. In preeclampsia, there is presence of  impaired
endothelial cell function and platelet aggregation  prior to the onset of elevated
thrombin and fibrin formation.[43-46].
The clinical syndrome of preeclampsia which occurs as a result of
placental ischemia  is  considered to be related to  a  protein known as Soluble
fms-like tyrosine kinase 1 (sFlt-1), which is produced  by the placenta. It exerts
its actions by binding to vascular endothelial growth factor (VEGF) and it also
binds to placental like growth factor (PLGF). Hence elevated concentration of
sFlt-1 leads to reduced concentration  of free VEGF & PLGF which in turn
causes impaired endothelial function[42]. The increased sFlt concentration of
corresponds to worsening of  disease . Maynard et al.[47] exhibited that soluble
placental derived  VEGF receptor (sFlt1) an antagonist of VEGF and PLGF is
not regulated. In case of preeclampsia which causes an elevated systemic sFlt1
that decreases after delivery [48,49,50] .The  growth factor produced by the
deciduas are  angiogenic in nature  that induces  PLGF. PLGF is  needed  for
the development of  placenta in the early stages. Levine et al states that
maternal systemic hypertension is a result of the maternal response to sFlt
which serves as a fetal rescue signal.[49,51] .
ANTI ANGIOGENIC PROTEINS
Soluble endoglin
Soluble endoglin (sEng) is a placental derived protein is a recent
parameter that sEng increases  several weeks prior to the clinical onset of
preeclampsia. [52] .This protein causes decreased endothelial nitric oxide-
dependent vasodilatation. This leads to maternal hypertension and endothelial
dysfunction. Soluble endoglin is a co receptor for TGF-β. This receptor is
present over the surface of the endothelial cells and syncytiotrophoblasts.
Soluble endoglin (sEng)  an angiogenic protein is present in the patients
with preeclampsia. There is a positive correlation  between the blood levels  of
sEng  and the progress , worsening of the disease. The levels of sEng declines
in the postpartum period. It is observed from the clinical studies that
measurement of both sEng and sFLT-1 proteins are found to be a better
predictor of preeclampsia than the measurement of either of the proteins. There
are certain studies in which elevated sEng levels are observed especially in
early onset of preeclampsia.
UTERINE VASCULAR CHANGES
The walls  of the  spiral arterioles is invaded by the interstitial and
endovascular trophoblasts .This migration transform the small masculoelastic
spiral arteries  into large dilated, tortuous channels which are the source of
blood supply to the human placenta.
The so formed blood vessels in the uterus and the placenta has low
resistance, low-pressure, high flow system..The mechanism by which the spiral
arterioles are transformed in to the uteroplacental arteries is known as the
physiological changes during pregnancy.[38] In case of a normal pregnancy
the vascular changes induced by the trophoblast are seen in the intervillous
space and in the inner third of the myometrium where the spiral arterioles
originate from the radial arteries. The changes in the blood vessels takes place
in the two stages . First stage being “the conversion of the decidual segments
of the spiral arterioles by a wave of endovascular trophoblast migration in the
first trimester.  and second stage being the involvement of myometrial
segments by a subsequent wave in the second trimester.”[38] .As a result of
these vascular changes  around 100 to 150 spiral arterioles are transformed
into dilated , tortuous, and funnel-shaped vessels that communicate via
numerous openings into the intervillous space.
On the other hand , minimal change in the blood vessels are observed
after placentation  in patients with preeclampsia  or fetal growth restriction . In
these pregnancies the changes in the blood vessels takes place only in the
decidual portion and the myometrial portion of spiral arterioles does not
undergo any change  .Thereby making the myometrial spiral arterioles sensitive
and responsive to the hormonal changes [38] .These changes in blood vessels
are also appreciated in a number of pregnancies associated with fetal growth
restriction[38,39,41] .Meekins and associates[4] have done studies which states
the  invasion  of trophoblast into  the blood vessels is not an all-or-none
phenomenon in case of both normal as well as pregnancies complicated by
preeclampsia.
Uterine vascular changes in normal and preeclamptic pregnancy ( FIG-1
lacental cytotrophoblasts invade the uterine wall where they breach eins
and extensively remodel maternal spiral arterioles
IMMUNOLOGY OF PREECLAMPSIA
There are other hypothesis for preeclampsia syndrome like loss of
maternal immune tolerance against the paternal derived placental and foetal
antigenic tissues. Tolerance dysregulation also explains an increased risk when
the paternal antigenic load is increased which is seen with two sets of paternal
chromosomes- “a double dose” as observed in molar pregnancies and in
trisomy 13.
It is perceived that preeclampsia is a result of non functioning of the
maternal immune system  which in turn fails to recognise the fetoplacental unit.
Death of extra villous cytotrophoblast occur due to increased synthesis of
immune cells which leads to elevated levels of TNF α .Women with
preeclampsia  have reduced amount of  HLA –G and HLA-E 18. This confirm
that there is a significant role of HLA in case of  impaired spiral arteriole
invasion. The natural killer cells secrete VEGF and placental growth factor
which are responsible for the interactions between these cells and trophoblasts
in a normal pregnancy. There is presence of elevated amounts of soluble fms
like tyrosine kinase, an antagonist of VEGF, PLGF in preeclamptic
women.[17,18].
Factors contributing to an enhanced immunologically mediated
inflammatory reaction include the placental micro particles which are
circulating in the maternal body. Maternal immune response syndrome is a
condition in which there is oxidative injury of the placenta , 2nd stage of the two
stage model hypothesis for preeclampsia. The syndrome occurs  due to
activation of immune system in the mother in response to the circulating
placental  micro particles. This has lead to the formation of a new hypothesis
called the placental debris hypothesis of preeclampsia.[54]
GENETIC CONFLICT HYPOTHESIS
Haig’s theory of  genetic conflict states that [55] the genes in the fetus
are selected to increase  the nutrient  transfer to the fetus. In contrast to this the
genes from the mother are selected to reduce the amount of transfer and
maintain the optimal level. A similar conflict between the genes that are
obtained from the mother  and the genes obtained from the father exists within
the fetal cells  which is known as the genetic imprinting phenomenon.
The conflict hypothesis have been demonstrated that elevation of
maternal blood pressure due to placental factors (fetal genes), whereas
reduction of blood pressure due to maternal factors . [55,56] . Genome-wide
linkage studies have identified three preeclampsia loci showing significant
linkage: 2p12, 2p25 and 9p13.[57] . Oudejans et al.[58] have recently
published the importance of genomic imprinting .Oudejans et al has
demonstrated the susceptibility locus on chromosome 10q22.1.
Diagnostic criteria of preeclampsia(ACOG 2014)
Prediction of Preeclampsia
A  well known of mechanism  of  pathophysiology of  preeclampsia is
impaired    trophoblastic  invasion of  the spiral  arteries  which increases
impedence of  flow to uterine arteries. Several studies have shown that
evidence of reduced uterine flow  is associated with the development of
preeclampsia.
Elevated  level of second trimester β- human chorionic gonodotropin (Β
HCG) have been identified in patients at risk for hypertensive disorders  during
pregnancy. Another  study demonstrated that in presence of  a  diastolic notch ,
the association of  serum  screening with alfa –feto-protein and human
chorionic gonodotrophin , improve sensitivity and  positive predivtive value to
91% and 41% respectively.
Regarding the placental protein -13 (PP-13), initial  studies showed
significant  decrease in preeclamptic women . Recently  another study did not
show any relationship between  PP-13 levels and  preeclampsia. Akolekar  et al
studied  placental  protein -13 (PP-13) associated  with  pregnancy  protein -A
(PAPP –A) and uterine  artery  Doppler in first trimester  in 200 preeclamptic
patients and in  410 normal pregnancies showing reduction in PP-13 levels
during early preeclampsia  but not in late preeclampsia  with positive predictive
value  for early preeclampsia  of 75% ,  while for  late preeclampsia of 49% .
Though in preeclampsia  PAPP-A was reduced  and  uterine  velocimetry
Doppler  was elevated , combination of these  parameters with  PP-13 does not
look to improve  sensitivity of  PP-13.
Inspite of  the promising results  heterogeneity  between studies
regarding  gestational age at time of study of population  has lead us to incline
towards the combination of  ultrasonographic and biochemical markers as
screening procedure of preeclampsia.
Maternal  echocardiography
In pregnancy, changes happen in cardiovascular system with initial
vasodilatative adaptation  of the maternal cardiovascular system which begins
in 1st trimester  as a result of invasion by spiral arteries  by the trophoblast.
Indeed  remodelling in the spiral arteries  contributes to 20% to 26% . Echo
parameters  of  cardiac  changes  in pregnancy  may  be, in normotensive
women  an important of pregnancy  complications  and indicator of
predisposition to cardiac  diseases.
Provocative  pressor tests
These are tests which assess blood pressure increase in  response to a
stimulus . They are cumbersome  and time consuming . Sensitivities  of all
these tests  range from 55to 70%  with specificity of  85% . They  include :
Angiotensin sensitivity test:
The abnormal vascular reactivity  of patients destined to develop
preeclampsia may be detected  several weeks before the development of
clinical signs  and symptoms and the degree of sensitivity to angiotensin II
may be used as a screening test to identify the patients at risk.
1. Roll over test:
It measures the hypertensive response in women at 28 to 32 weeks who
are resting  in the left lateral decubitus  position  and then  roll over  to a supine
position. A positive test  is an elevation of 20 mmHG or more in blood pressure
when patients roll over from the  lateral to the supine position .
2. Urinary calcium:
Several studies have demonstrated  that preeclampsia is associated  with
hypocalciuria .  An  urinary calcium concentration  equal to or less than 12 mg/
dl in a 24 hr collection  has positive and negative predictive value of  85 and
91% respectively , for the diagnosis of preeclampsia .Determination  of
calcium creatinine ratio  in a randomly obtained urine sample seems to be
accurate  as 24 hr collection .
New biochemical markers :
Several new biochemical markers associated with preeclampsia are:
 Adrenomedulin
 Podocyturia
 mRNA
 Placental protein 13
 PAPP –A
 Activin  A and  inhibin A
 P- selectin
 Pentraxin  3
 Fibronectin
 Heat shock protein
 Fms like tyrosin kinase 1
 Soluble endoglin
 Cell free fetal DNA
Chronic hypertension in pregnancy
Chronic hypertension  complicating pregnancy accounts for about 0.5-
3% .Increase in incidence of obesity and a high maternal age in today’s world
is expected to increase the incidence of chronic hypertension complicating
pregnancies..Hypertension before  pregnancy or before 20th week of  gestation
on more than one occasion atleast 4-6hours apart or persistence of hypertension
for 12weeks postpartum is defined as chronic  hypertension.
It is very difficult to diagnose chronic hypertension in patients who
attend the antenatal clinic for the first time after 16 weeks of pregnancy
because there is a physiological fall in blood pressure after 16 weeks of
gestation. This physiological fall in blood pressure might mask the original
findings of elevated blood pressure and can be recorded as a normal blood
pressure which in turn will eventually be increased in the third trimester. These
women are more prone to develop gestational hypertension.
Classification of chronic hypertension :
1. Mild hypertension
Systolic blood pressure of 140-159mmHg or diastolic blood pressure of
90-109mmHg
2.Severe hypertension Systolic Bp 160/110mmHg or >160/110mmHg
Etiology of  chronic hypertension:
In 90% of cases of chronic hypertension is due to essential hypertension
and remaining 10% cases it is  due to an  underlying  disorder .i.e.chronic renal
disease, endocrine disorder,collagen vascular disease.
1.Renal  Diseases
 Renal parenchymal diseases such as glomerular nephritis,reflux
nephropathy, adult polycytic kidney diseases.
 Renovascular  hypertension
2.Endocrine  disorder
 Diabetes with vascular involvement
 Thyrotoxicosis
 Pheochromocytoma
 Primary aldosteronism
 Cushing syndrome
3.Collegen vascular disease
 SLE
 Scleroderma
4.Others
 Aortic coarctation
 Increased intracranial pressure
Maternal and perinatal risk of  chronic hypertension
There is an increased risk of development of superimposed preeclampsia
and abruptio placentae in case of chronic hypertension complicating
pregnancies.It observed  that  about  10 to 25% patients  with mild
hypertension  develop preeclampsia  . On the other hand, about  50%  patients
with severe chronic hypertension develops  preeclampsia . The overall rate of
superimposed preeclampsia is 25%. However, it is observed that certain factors
contribute to the rate significantly and presence  of  hypertension for 4 years
(31% versus 22%), history of  preeclampsia in previous pregnancies (32%
versus 23%), and in those who have a diastolic blood pressure is 100–110 mm
Hg compared to who have a diastolic blood pressure is less than 100 mm Hg at
baseline.
PREECLAMPSIA SUPERIMPOSED ON CHRONIC HYPERTENSION
Criteria for diagnosis:
A) New-onset proteinuria ≥ 300mg/24 hours in  hypertensive women who
had no proteinuria before 20 weeks of gestation.
B) A sudden increase in proteinuria or blood pressure or platelet count <
100,000/μL in a woman with hypertension and proteinuria before 20
weeks of gestation[22].
HOMOCYSTEINE
Homocysteine formed as a result of metabolism of the essential amino
acid methionine is a sulphur containing amino acid.It is formed at the junction
of  metabolism of  the  amino acid methionine  and synthesis of  cysteine and
taurine . Metabolism(fig 1) of homcystiene occurs via two biochemical
pathways–
1. re-methylation,in which homocysteine is transformed into
methionine , and
2. trans-sulfuration, in which homocysteine is transformed into cysteine
and taurine.
Hyperhomocysteinemia has been epidemiologically and clinically found
to be associated in various conditions like neural tube defects, spontaneous
abortion, placental abruption andlow birth weight.
HOMOCYSTEINE METABOLISM
Homocysteine , a sulphur containing amino acid  does not form proteins.
Metabolism of this amino acid is at the juncture of two metabolic pathways:
remethylation and transsulfuration.
In remethylation reaction methionine is formed as a result of
acceptance of a methyl group from N-5 methyltetrahydrofolate or betaine by
homocysteine.  The reaction with N-5 methyltetrahydrofolate takes place in all
the body tissues and is vitamin B12 dependent .Whereas the reaction with
betaine takes place only in liver and is not dependent on vitamin B12. S-
adenosyl methionine(SAM) is formed when ATP activates a methionine. SAM
is a universal methyl donor.A by-product of these methylation reactions is  S-
adenosyl homocysteine(SAH) which on hydrolysis regenerates homocyteine
making it available for the next new cycle.
In transsulfuration pathway, cystathionine is formed by condensation
of homocysteine and serine with the help of the enzyme cystathionine synthase
which contains pyridoxal-50-phosphate(PLP). It is an irreversible reaction.
Cystathionine sulphate is excreted in the urine. Thus the excess homocysteine
not required for methyl transfer is channelled to transsulfuration pathway.
HYPERHOMOCYSTEINEMIA IN HUMANS:
CAUSES OF HYPERHOMOCYSTEINEMIA[59]
A) ENZYME DEFECTS:
1) Cystathionine synthase ( Homocystinuria-1)
2) Homocysteine methyl transferase( Homocystinuria-2)
3) Methyl THFA reductase deficiency ( Homocystinuria-3)
4) Cystathionase deficiency ( cystathioninuria)
B) ACQUIRED CAUSES
1) Vitamin B12, Folic acid and pyridoxine deficiency.
2) Hypothyroidism, chronic renal failure.
3) Antifolate Drugs
HOMOCYSTEINE IN NORMAL PREGNANCY
The normal serum homocysteine level in non pregnant adult female
range between 5 and 15 μmol/L. It exists in two forms. 75 to 80% exists as
protein bound form and 15-25 % exist as acid soluble free form [60].
Hemodilution, reduced levels of albumin and increase in the demand of the
amino acid methionine by both the mother and the fetus during pregnancy leads
to reduced  amount of  homocysteine . Of  this the decrease in serum albumin
level correlates well with the serum homocysteine level.
During normal pregnancy the homocysteine levels are significantly
lower in all trimesters compared with non pregnant control values. Walker et
al[61] in a study of normal pregnant women and non pregnant women,
measured serum homocysteine level by chromatography and found that the
lowest level of homocysteine was found during the second trimester and
homocysteine rises in the third trimester. However this rise is still well below
the normal non pregnant level.[61,62] The normal level of homocysteine level
during normal pregnancy is:
 First trimester- 3.9-7.3μmol/L
 Second trimester-3.5-5.3 μmol/L
 Third trimester -3.3-7.5 µmol/L
HOMOCYSTEINE IN PREECLAMPSIA AND OTHER
PREGNANCY RELATED DISORDERS:
Numerous studies have found an association between homocysteine and
various pregnancy related disorders. Klai et al[63] assessed the genetic make
up of patients with proven placental vasculopathies and found an association
with MTHFRA1298C polymorphism which leads to hyperhomocysteinemia.
Elevated homocysteine levels are associated with development of vasculopathy
of the placenta. Many hypothesis have been proposed for the pathogenesis of
homocysteine induced vasculopathy and endothelial dysfunction.
EFFECT OF HYPERHOMOCYSTEINEMIA ON PREGNANCY
MECHANISMS BY WHICH HOMOCYSTEINE MAY INDUCE
VASCULAR INJURY AND ENDOTHELIAL DYSFUNCTION:
 Increased  amounts of monocyte  chemoattractant  protein -1  and
interleukin 8 by the amino acid  homocysteine , in turn leads  to
recruitment  of leukocytes [64].
 The thiolactone is a metabolite of homocysteine that combines with
LDL cholesterol and produces aggregrates. These aggregates are then
taken up by the circulating macrophages in the arterial intima and forms
foam cells which in turn release lipid into the atherosclerotic plaques.
[65].
 This thiolactone also induces apoptosis in cultured trophoblasts thereby
leading to placental dysfunction[65]
 Homocysteine decreases the utero placental flow by increasing the
smooth muscle proliferation and enhancing the collagen production.
 Attenuation of the tissue plasminogen binding sites in the endothelial
cells, factor VIIa and V activation, protein C and heparin sulphate
inhibition, increased fibrinopeptide A and prothrombin fragments 1 and
2, increased blood viscosity and decreased antithrombotic activity of the
endothelial cells due to change in thrombomodulin function are all
considered to be the prothrombotic effects of homocysteine. [67-72]  All
these factors promotes thrombosis of spiral artery.
 Oxidation of reduced homocysteine leads to formation of free radicals
which damage the endothelial cells due to oxidative stress resulting in
endothelial cell activation [73,74].
 The pro aggregatory effects of homocysteine and impaired endothelial
function lead to marked platelet accumulation.
HYPERHOMOCYSTEINEMIA IN PREECLAMPSIA
REVIEW OF CLINICAL STUDIES:
Numerous studies have proved the association of hyperhomocysteinemia
in preeclampsia.[82-89]. Similarly the level of homocysteine correlated with
the severity of preeclampsia[86].Md.Mazammel Hoque et al[82] compared the
homocysteine levels in healthy pregnant, preeclamptic and eclamptic pregnant
women and found that homocysteine levels are significantly raised in
preeclampsia .Mahal M et al[83] compared serum homocysteine and HDL
levels in preeclamptic/ eclamptic mother and found that both HDL and
homocysteine are increased in women with preeclampsia/eclampsia.
Singh Urmila et al[84] studied 90 women and found that homocysteine
levels were significantly different between non preeclamptic and preeclamptic
mothers . In that study, homocysteine levels correlated directly with the degree
of hypertension. And he proved that maternal homocysteine levels in normal
pregnant women were significanty lower than non pregnant levels.
Likewise, Hasanzadeg et al [85] and Stolkova et al[86] state that the
homocysteine levels in preeclamptic mothers were significantly raised.
Ingec et al[89] compared the homocysteine levels among mild and
severe preeclampsia with eclampsia and concluded that homocysteine levels
are significantly elevated in severe preeclampsia and eclampsia, with
significant difference between mild and severe preeclamptic group. However
in that study , it was concluded that there was not much difference between
normal pregnancy and in mild preeclampsia. Stolkova et al[86] did a study on
the distribution of homocysteine levels in preeclamptic women and found that
there is an association between serum homocysteine levels and the severity of
preeclampsia.
Makedos and Papanicollou et al[87] compared maternal homocysteine,
folic acid and B12 levels among women with preeclampsia and found that
hyperhomocysteinemia is associated with poor maternal and fetal outcome and
found that hyperhomocysteinemia occurred in preeclampsia independent of
maternal folate and B12 levels.of preeclampsia.
The Hordaland study[97] showed that women with Homocysteine levels
more than 15μ/L are more likely to suffer from pregnancy related
complications and are also associated with poor maternal and fetal outcome.
Baksu et al [88] studied the homocysteine levels in pregnancies complicated
with severe and non severe preeclampsia and found that at a homocysteine
level of above 15μmol/L the maternal and fetal morbidities increased and also
proved that homocysteine levels differed significantly among the severe and
non severe group.
HYPERHOMOCYSTEINEMIA IN OTHER PREGNANCY
RELATED CONDITIONS:
 Hyperhomocysteinemia is found to have some association in neural
tube defects.[90]
 Hyperhomocysteinemia in amniotic fluid is associated with small for
gestational babies.[91] 32
 Hyperhomocysteinemia is an independent marker for low birth
weight.[92]
 Hyperhomocysteinemia together with uterine artery Doppler could
predict IUGR[93] and hyperhomocysteinemia in preeclampsia is
associated with IUGR.[87] The Hordaland homocysteine study[97]
showed that there is an association between hyperhomocysteinemia
and IUGR independent of preeclampsia.
 Hyperhomocysteinemia in preeclampsia is inversely related to insulin
sensitivity.[94]
 Hyperhomocysteinemia is an independent risk factor for the
development of placental abruption and infarction.[95,97]
 Hyperhomocysteinemia is one of the causes for recurrent pregnancy
losses in the first trimester
AIM OF THE STUDY
STUDY OF HOMOCYSTEINE LEVELS IN PREECLAMPTIC WOMEN
AND ITS ASSOCIATION WITH THE SEVERITY OF THE DISEASE
AIMS &OBJECTIVES
1. To find  the association of  the homocysteine  levels in Preeclampsia
and  normal  pregnancy
2. To know the prediction cut off values of serum homocysteine  levels
and to  find out the  severity of preeclampsia.
BENEFITS OF THE STUDY
1) This study evaluates the significant role of homocysteine in
preeclampsia.
2) To find out vascular complication early if hyperhomocysteinemia exists.
3) To know the fetal complications early and improve the maternal and
fetal outcome by increasing patient surveillance.
METHODOLOGY
1) All the patient attending AN OPD and Labour ward who are
undergoing preeclamptic workup were included and compared to equal
number of healthy normotensive pregnant women
2) Blood pressure was recorded (two measurements 6 hrs apart in the semi
recumbent position)
3) All the patients underwent a detailed history taking and examination as
mentioned in the proforma.
All these patients were subjected to blood investigations like Complete
hemogram, urine routine, renal function tests ,liver function tests, serum
fibrinogen and  serum uric acid,  they also had  obstetrics ultra sonogram and
fundoscopy, 24 hours urinary protein excretion was done for all patients
included in the study. Urine culture were done for appropriate patients.
Peripheral smear study was done for all patients to exclude megaloblastic
anaemia, dimorphic anaemia and HELLP Serum folate and vitaminB12 levels
could not be estimated because of limited resources. Hence the presence of
megaloblastic or dimorphic anemia are taken as indirect indictors of folate or
B12 deficiency and these patients were ruled out of the study. Once vitamin
deficiencies  were excluded, serum homocysteine level was estimated.
For the measurement of serum homocysteine, 5 mL of blood was
drawn from the antecubital vein after overnight fasting and the specimen was
transported immediately to lab and centrifugation was done at 3000rpm for 5-7
mts and the clear serum is transferred to a plastic vial and stored in refrigerator
until analysis. Serum homocysteine was measured by fluorescence polarization
immunoassay (FPIA) run on Abbott’s AxSYM machine using Abbott’s kit.
STUDY DESIGN :
Case control study
DURATION OF STUDY- 9 MONTHS
PLACE OF STUDY :
Antenatal outpatient department,  Labour ward  and  Antenatal ward ,
Dept of Obstetrics & Gynaecology , Govt Kilpauk medical college &Hospital ,
Chennai.
SAMPLE SIZE:
N=2X(4X4)(0.84+1.96)2/( Mean difference=3)2 =  27.80=30  each group
n-sample size
r-ratio of cases to contols(=1)
Zβ-Represents the desired power of the study(for 80%-0.84)
Zα/2-Represents the desired level  of statistical significance (for 0.05-1.96)
s-statistical difference(σ-)
cases -30
control -30
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INCLUSION CRITERIA:
CASES:
1) Pregnant women with BP≥140/90mmHG (previously normotensive
women) on atleast 2 occasions 6 hours apart.
2) Gestational age 28-40weeks (sure of gestational age by LMP or USG in
1st or early 2nd trimester).
CONTROL:
Healthy pregnant normotensive women of gestational age of 28-
40weeks.
EXCLUSION CRITERIA:
1)Chronic hypertension
2) Gestational Diabetes mellitus
3)Type 1&2 Diabetes mellitus
4) Connective tissue disorders
5) Multiple pregnancy
6) Liver diseases
7) Severe Anaemia
8)Smoking
9)Obesity
10)Pregnancy with APLA Syndrome
STATISTICAL ANALYSIS
The mean and standard deviation of the serum homocysteine will be
calculated and student 't’ test is used to compare mean
OBSERVATION AND RESULT
Correlation of variables with preeclampsia
TABLE -1
Maternal Age  # preeclampsia
Crosstab
PREECLAMP
SIA
NO YES Total
AGE
GROU
P
UP TO 25
YEARS
Count 8 6 14
% within
PREECLAMPSIA
26.7% 20.0% 23.3%
% of Total 13.3% 10.0% 23.3%
26 YEARS &
ABOVE
Count 22 24 46
% within
PREECLAMPSIA
73.3% 80.0% 76.7%
% of Total 36.7% 40.0% 76.7%
Total Count 30 30 60
% within
PREECLAMPSIA
100.0% 100.0% 100.0%
% of Total 50.0% 50.0% 100.0%
Chi-Square Tests
Value df
Asymp.
Sig. (2-
sided)
Exact Sig.
(2-sided)
Exact Sig.
(1-sided)
Pearson Chi-
Square
.373a 1 .542
Continuity
Correctionb
.093 1 .760
Likelihood
Ratio
.374 1 .541
Fisher's Exact
Test
.761 .381
Linear-by-
Linear
Association
.366 1 .545
No of Valid
Cases
60
Among  preeclamptic   women in the age  group  up  to  25 years there
were  6  women  and  above  26  Years  were  24 women.  Among
normotensive  women  up  to  25years  were  8 women  and  above 26 years
were  22  women .Pearson Chi-square value 0.373  , p=0.542. Hence  maternal
ge  is not statistically  significant in  relation  to preeclampsia.

TABLE -2
Gravida # preeclampsia
Crosstab
PREECLAMPSIA
NO YES Total
GRAVID
A
1 Count 6 16 22
% within
PREECLAMPSIA
20.0% 53.3% 36.7%
% of Total 10.0% 26.7% 36.7%
2 Count 18 6 24
% within
PREECLAMPSIA
60.0% 20.0% 40.0%
% of Total 30.0% 10.0% 40.0%
3 Count 6 8 14
% within
PREECLAMPSIA
20.0% 26.7% 23.3%
% of Total 10.0% 13.3% 23.3%
Total Count 30 30 60
% within
PREECLAMPSIA
100.0% 100.0% 100.0%
% of Total 50.0% 50.0% 100.0%
Among  preeclamptic  women, primigravida  were  16,  2nd gravid  were
6,  3rd gravida were  8. Among  normotensive  women, primigravida  6, 2nd
gravida were 18, and 3rd gravida were  6. Pearson Chi-square -10.831  p=0.004
The degree of gravidity has significant  relation to  preeclampsia.
Chi-Square Tests
Value df
Asymp. Sig. (2-
sided)
Pearson Chi-Square 10.831a 2 .004
Likelihood Ratio 11.282 2 .004
Linear-by-Linear Association 1.802 1 .180
No of Valid Cases 60
TABLE -3
Gestational age # preeclampsia
Group Statistics
PRE
ECL
AMP
SIA N Mean
Std.
Deviation
Std. Error
Mean
P
GES
AGE
YES 30 36.03 1.326 .242 0.372
NO 30 35.70 1.535 .280
Mean  gestatinal  age  for  preeclamptic  women   is  36  and
Normotensive  women is  35,  t – test  for  equality  for  mean  0.9. p=0.372 .
Hence  gestational  age  is not statistically  significant  in  relation  to
preeclampsia.
TABLE-4
B MI #  preeclampsia
Group Statistics
PRE
ECL
AMP
SIA N Mean
Std.
Deviation
Std. Error
Mean
P
PRE PREG
BMI
YES 30 24.713 2.4710 .4511
NO 30 21.020 1.1941 .2180 0.000
Mean  BMI  for  preeclamptic  women  is  24  and   Normotensive
women  is  21 ,  t- test for equality  for  means 7.371 ,   p=0.000 .Hence  BMI
is statistically   significant   in  relation  to  preeclampsia.
TABLE-5
Serum Homocysteine # preeclampsia
Group Statistics
PRE
ECL
AMP
SIA N Mean
Std.
Deviation
Std. Error
Mean
P
SER
HOMOCYSTEI
NE
YES 30 16.923 2.3218 .4239 0.000
NO 30 9.647 1.4088 .2572
Mean serum  Homocysteine  in preeclamptic women is  16.9 and in
Normotensive  women  is  9.6,  t- test  for  equality  for  mean  14,  p=0.000
which is  stastically  very  significant. Hence  Serum Homocysteine  is a
significant  predictor    of   preeclampsia.
TABLE -6
Urine albumin  #  preeclampsia
Crosstab
PREECLAMPSI
A
NO YES Total
URI
ALBUMIN
1+ Count 0 1 1
% within
PREECLAMPSIA
.0% 3.3% 1.7%
2+ Count 0 9 9
% within
PREECLAMPSIA
.0% 30.0% 15.0%
3+ Count 0 3 3
% within
PREECLAMPSIA
.0% 10.0% 5.0%
4+ Count 0 17 17
% within
PREECLAMPSIA
.0% 56.7% 28.3%
NIL Count 30 0 30
% within
PREECLAMPSIA
100.0% .0% 50.0%
Total Count 30 30 60
% within
PREECLAMPSIA
100.0% 100.0% 100.0%
Pearson Chi-square 60.000  ,p= 0.000 which is very significant .Hence  urine
albumin has  very  significant relation  to  preeclampsia.
Chi-Square Tests
Value df
Asymp. Sig. (2-
sided)
Pearson Chi-Square 60.000a 4 .000
Likelihood Ratio 83.178 4 .000
N of Valid Cases 60
TABLE-6
Serum Uric acid # preeclampsia
Group Statistics
PRE
ECL
AMP
SIA N Mean
Std.
Deviation
Std. Error
Mean
P
URIC
ACID
YES 30 6.82 .780 .142 0.000
NO 30 5.20 .459 .084
Mean serum uric  acid  level  in  preeclampsia  is  6.8  and  in
Normotensive  women  is  5 ,  t- test  for  equality  Of   means is 9.7,  p=0.000
which  is  very  significant  .Hence serum uric acid  has statistically significant
relation  to  preeclampsia.
TABLE- 7
24 hr urinary protein  # preeclampsia
Group Statistics
PRE
ECL
AM
PSI
A N Mean
Std.
Deviation
Std. Error
Mean
P
24HR URI
PROTEINE
YES 30 395.10 107.310 19.592
NO 30 186.40 15.867 2.897 0.000
Mean  24 hr  urinary  protein  in  preeclamptic  women  is  395  and  in
Normotensive  women  is  186 , t-test  for  equality  of  mean is 10.5 ,  p
=0.000  which  is  very  significant. Hence  24 hr urinary  protein  has
statistically significant  relation  to  preeclampsia.
ROC CURVE FOR VARIABLES IN RELATION TO
PREECLAMPSIA
AREA UNDER  CURVE- 0.998333
STATISTICAL  SIGNIFICANCE  P <0.0001
Hence  serum  Homocysteine  is a statistically   significant  variable  to
predict preeclampsia with   p value <0.0001
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ROC CURVE
Variable SER_HOMOCYSTEINE
SER HOMOCYSTEINE
Classification variable PREECLAMPSIA
Sample size 60
Positive group : PREECLAMPSIA = 1 30
Negative group : PREECLAMPSIA = 0 30
Disease prevalence (%) unknown
Standard Errora 0.00254
AREA UNDER THE ROC CURVE
Area under the ROC curve (AUC) 0.998333
Standard Errora 0.00254
95% Confidence intervalb 0.937079 to 1.000000
z statistic 196.319
Significance level P (Area=0.5) <0.0001
YOUDEN INDEX
Youden index J 1.0000
Associated criterion >12.2
ROC CURVE FOR BLOOD UREA
AREA UNDER  CURVE-0.894444
STATISTICAL SIGNIFICANCE P <0.0001
Hence blood urea is a statistically  significant  variable  in  relation  to
preeclampsia.
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ROC curve
Variable UREA
Classification variable PREECLAMPSIA
Sample size 60
Positive group : PREECLAMPSIA = 1 30
Negative group : PREECLAMPSIA = 0 30
Disease prevalence (%) unknown
Area under the ROC curve (AUC)
Area under the ROC curve (AUC)
0.894444
Standard Errora 0.0396
95% Confidence intervalb 0.788001 to 0.958932
z statistic 9.959
Significance level P (Area=0.5) <0.0001
Youden index
Youden index J 0.6333
Associated criterion >24
ROC FOR SERUM CREATININE
AREA UNDER CURVE-0.827778
STATISTICAL SIGNIFICANCE P <0.0001
Hence  serum  creatinine  is a statistically  significant  variable  in
relation  to preeclampsia.
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ROC curve
Variable CREATININE
Classification variable PREECLAMPSIA
Sample size 60
Positive group : PREECLAMPSIA = 1 30
Negative group : PREECLAMPSIA = 0 30
Disease prevalence (%) Unknown
Area under the ROC curve (AUC)
Area under the ROC curve (AUC)
0.827778
Standard Errora 0.0539
95% Confidence intervalb 0.708357 to 0.913004
z statistic 6.080
Significance level P (Area=0.5) <0.0001
Youden index
Youden index J 0.6333
Associated criterion >0.6
ROC CURVE FOR 24HRS URINARY PROTEIN
AREA UNDER CURVE -0.97552
STATISTICAL SIGNIFICANCE  P <0.0001
Hence  24hrs  urinary protein  is a statistically  significant  variable  in
relation  to  preeclampsia.
24HR URINE PROTEIN
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Sensitivity: 96.0
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ROC curve
Variable 24HR_URINE_PROTEIN
24HR URINE _ PROTEINE
Classification variable PREECLAMPSIA
Sample size 60
Positive group : PREECLAMPSIA =
1
30
Negative group : PREECLAMPSIA =
0
30
Disease prevalence (%) unknown
Area under the ROC curve (AUC)
Area under the ROC curve (AUC)
0.97552
Standard Errora 0.000
95% Confidence intervalb 0.940371 to 1.000000
Significance level P (Area=0.5) <0.0001
Youden index
Youden index J 1.0000
Associated criterion >220
ROC CURVE FOR SERUM BILIRUBN
AREA UNDER CURVE -0.874444
STATISTICAL SIGNIFICANCE p < 0.0001
Hence  serum  bilirubin  is a statistically  significant  variable  in
relation  to preeclampsia.
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ROC curve
Variable SER_BILIRUBIN
SER BILIRUBIN
Classification variable PREECLAMPSIA
Sample size 60
Positive group : PREECLAMPSIA = 1 30
Negative group : PREECLAMPSIA = 0 30
Disease prevalence (%) unknown
Area under the ROC curve (AUC)
Area under the ROC curve (AUC)
0.874444
Standard Errora 0.0441
95% Confidence intervalb 0.763456 to 0.945898
z statistic 8.493
Significance level P (Area=0.5) <0.0001
Youden index
Youden index J 0.5667
Associated criterion >0.8
ROC CURVE FOR PRE PREGNANT BMI
AREA  UNDER  CURVE -0.918889
STATISTICAL SIGNIFICANCE p <0.0001
Hence   prepregnant  BMI  is a statistically  significant  variable  in
relation  to preeclampsia.
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ROC curve
Variable PRE_PREG_BMI
PRE PREG BMI
Classification variable PREECLAMPSIA
Sample size 60
Positive group : PREECLAMPSIA = 1 30
Negative group : PREECLAMPSIA = 0 30
Disease prevalence (%) unknown
Area under the ROC curve (AUC)
Area under the ROC curve (AUC)
0.918889
Standard Errora 0.0437
95% Confidence intervalb 0.819016 to 0.973660
z statistic 9.588
Significance level P (Area=0.5) <0.0001
Youden index
Youden index J 0.8333
Associated criterion >23.2
CORRELATION OF SERUM HOMOCYSTEINE WITH OTHER
VARIABLES IN RELATION TO PREECLAMPSIA
Comparison of ROC curves
Variable 1 SER_HOMOCYSTEINE
SER HOMOCYSTEINE
Variable 2 24HR_URI_PROTEIN
24HR URI PROTEIN
Variable 3 SERUM CREATININE
Variable 4 BLOOD UREA
Variable 5 PRE_PREG_BMI
PRE PREG BMI
Variable 6 SER_BILIRUBIN
SER BILIRUBIN
Classification variable PREECLAMPSIA
Sample size 60
Positive group : PREECLAMPSIA = 1 30
Negative group : PREECLAMPSIA = 0 30
AUC SE a 95% CI b
SER_HOMOCYSTEINE 0.998 0.00254 0.937 to 1.000
24HR_URI_PROTEIN 0.975 0.000 0.930 to 1.000
CREATININE 0.828 0.0539 0.708 to 0.913
UREA 0.894 0.0396 0.788 to 0.959
PRE_PREG_BMI 0.919 0.0437 0.819 to 0.974
SER_BILIRUBIN 0.874 0.0441 0.763 to 0.946
SER_HOMOCYSTEINE ~ 24HR_URI_PROTEIN
Difference between areas 0.00167
Standard Errorc 0.00254
95% Confidence Interval -0.00331 to 0.00664
z statistic 0.657
Significance level P = 0.5114
SER_HOMOCYSTEINE ~ CREATININE
Difference between areas 0.171
Standard Errorc 0.0535
95% Confidence Interval 0.0657 to 0.275
z statistic 3.188
Significance level P = 0.0014
SER_HOMOCYSTEINE ~ UREA
Difference between areas 0.104
Standard Errorc 0.0395
95% Confidence Interval 0.0266 to 0.181
z statistic 2.633
Significance level P = 0.0085
SER_HOMOCYSTEINE ~ PRE_PREG_BMI
Difference between areas 0.0794
Standard Errorc 0.0430
95% Confidence Interval -0.00477 to 0.164
z statistic 1.849
Significance level P = 0.0644
SER_HOMOCYSTEINE ~ SER_BILIRUBIN
Difference between areas 0.124
Standard Errorc 0.0438
95% Confidence Interval 0.0380 to 0.210
z statistic 2.827
Significance level P = 0.0047
ROC curve analysis of serum homocysteine and other variables  with
respect to preeclampsia
Homoc
ysteine
urea Creatini
ne
24hruri
ne
protein
BMI Serum
bilirubin
sensitivity 96 83 86 86 83 66.7
spcificity 100 80 76 82 100 90
AUC 0.99833 0.8944 0.82777 0.97552 0.918 0.874444
criterion >12.4 >24 >0.6 >220 >23.2 >0.8
probability <0.0001 <0.0001 <0.0001 <0.0001 <0.001 <0.0001
Among  all  the  variables  serum  Homocysteine  has  got the
highest  sensitivity,  specificity  and  statistical  significance
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P VALUE  of  serum Homocysteine  against  24hr urinary protein is
0.51 which  is  not  statistically  significant . Against  SERUM CREATININE
is  0.0014  which is statistically  significant  .Against UREA  is  0.0085
which  is statistically significant.Aginst  PRE  PREGNANT  BMI  is  0.06
which  is  not statistically significant.Aainst  SERUM BILIRUBIN  is   0.0047
which  is  statistically  significant.
Serum Homocysteine  has  got the highest  area  under  curve
values  in  ROC followed by 24hr urine protein. SERUM
HOMOCYSTEINE ROC CUT OF VALUE IS >12.4.
Correlation of Serum Homocysteine with the Maternal morbidities of
preeclampsia
Serum Homocysteine #  Pulmonary Edema
Group Statistics
PUL
MON
ARY
EDE
MA N Mean
Std.
Deviation
Std. Error
Mean
P
SER
HOMOCYSTEI
NE
YES 6 18.300 1.4014 .5721 0.105
NO 24 16.579 2.3984 .4896
P =0.105 .In our study  there  was  no  association  between  maternal
serum  Homocysteine  level  and complication of  preeclampsia like
pulmonary  edema.
Acute Kidney Injury #  Serum Homocysteine
Group Statistics
AKI N Mean
Std.
Deviation
Std. Error
Mean
P
SER
HOMOCYSTE
INE
YES 4 18.175 1.2420 .6210 0.254
NO 26 16.731 2.4040 .4715
P=0.254 . In our study  there  was  no  association  between  maternal
serum  Homocysteine  level  and complication of preeclampsia like  Acute
kidney  injury .
DIVC # Serum Homocysteine
Group Statistics
DIV
C N Mean
Std.
Deviation
Std. Error
Mean
P
SER
HOMOCYSTEIN
E
YES 12 18.117 1.6508 .4765 0.019
NO 18 16.128 2.3995 .5656
P=0.019 . In our  study  there  was association  between  maternal  seum
Homocysteine   level  and complication of preeclampsia like    DIVC
HELLP Syndrome #  Serum Homocysteine
Group Statistics
HEL
LP N Mean
Std.
Deviation
Std. Error
Mean
P
SER
HOMOCYSTEIN
E
YES 4 18.700 .5354 .2677 0.101
NO 26 16.650 2.3741 .4656
P=0.101 . In our study  there  was  no  association  between  maternal
serum  Homocysteine  level  and complication of preeclampsia like  HELLP
Syndrome .
Abruption # Serum homocysteine
Group Statistics
ABR
UPTI
ON N Mean
Std.
Deviation
Std. Error
Mean
P
SER
HOMOCYSTEI
NE
YES 12 18.275 1.6826 .4857 0.007
NO 18 16.022 2.2836 .5382
P = 0.007 . In our study  there  was association  between  maternal
serum  Homocysteine  level  and complication of preeclampsia like  Abruptio
placenta.
Atonic PPH  # Serum Homocysteine
Group Statistics
ATO
NIC
PPH N Mean
Std.
Deviation
Std. Error
Mean
P
SER
HOMOCYSTEI
NE
YES 10 18.160 1.4206 .4492 0.037
NO 20 16.305 2.4627 .5507
P=0.037 .In our study  there  was  association  between  maternal
homocysteine level  and complication of preeclampsia like  Atonic PPH.
Correlation of Serum  Homocysteine with Fetal Growth Restriction
Group Statistics
IUG
R N Mean
Std.
Deviation
Std. Error
Mean
P
SER
HOMOCYSTEI
NE
YES 19 17.074 2.3139 .5309
0.649
NO 11 16.664 2.4246 .7310
P= 0.649 . In our  study there  was  no  association  between  maternal
serum  Homocysteine  level  and complication of preeclampsia  like   FGR.
Correlation of Serum Homocysteine with IUD
IUD # Serum Homocysteine
Group Statistics
IUD N Mean
Std.
Deviation
Std.
Error
Mean
P
SER
HOMOCYSTE
INE
YES 3 17.500 1.0000 .5774 0.658
NO 27 16.859 2.4276 .4672
P=0.658. In our study  there was  no  association between  maternal
serum  Homocysteine  level  and complication of preeclampsia like   IUD .
ROC CURVE FOR SERUM HOMOCYSTEINE IN RELATION
TO MATERNAL MORBIDITIES
ROC CURVE FOR ABRUPTIO PLACENTA
SER HOMOCYSTEINE
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ROC curve
Variable SER_HOMOCYSTEINE
SER HOMOCYSTEINE
Classification variable ABRUPTION
Sample size 30
Positive group : ABRUPTION = 1 12
Negative group : ABRUPTION = 0 18
Disease prevalence (%) unknown
Area under the ROC curve (AUC)
Area under the ROC curve (AUC)
0.773148
Standard Errora 0.0853
95% Confidence intervalb 0.584299 to 0.905084
z statistic 3.204
Significance level P (Area=0.5) 0.0014
Youden index
Youden index J 0.5000
Associated criterion >15.3
Area under curve -0.77314
Statistical significance p=0.0014
In  our study  maternal complication of preeclampsia like  Abruptio
placenta  has significant statistical association  with   maternal   serum
homocysteine  level  of  >15.3µmol/l.
ROC CURVE FOR DIVC
ROC curve
Variable SER_HOMOCYSTEINE
SER HOMOCYSTEINE
Classification variable DIVC
Sample size 30
Positive group : DIVC = 1 12
Negative group : DIVC = 0 18
SER HOMOCYSTEINE
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0
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100
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 Sensitivity: 100.0
 Specificity: 50.0
 Criterion : >15.3
Disease prevalence (%)
unknown
Area under the ROC curve (AUC)
Area under the ROC curve (AUC)
0.736111
Standard Errora 0.0919
95% Confidence intervalb 0.544072 to 0.879204
z statistic 2.570
Significance level P (Area=0.5) 0.0102
Youden index
Youden index J 0.5000
Associated criterion >15.3
Area under curve -0.736111
Stastical significance p=0.0102
In  our study  maternal complication of preeclampsia  like  DIVC  has
significant statistical association  with  maternal  serum  Homocysteine  level
of  >15.3µmol/l
ROC CURVE FOR ATONIC PPH
ROC curve
Variable SER_HOMOCYSTEINE
SER HOMOCYSTEINE
Classification variable ATONIC_PPH
ATONIC PPH
Sample size 30
Positive group : ATONIC PPH = 1 10
SER HOMOCYSTEINE
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 Sensitivity: 100.0
 Specificity: 55.0
 Criterion : >15.5
Negative group : ATONIC PPH = 0 20
Disease prevalence (%) unknown
Area under the ROC curve (AUC)
Area under the ROC curve (AUC)
0.702500
Standard Errora 0.0944
95% Confidence intervalb 0.508639 to 0.854531
z statistic 2.146
Significance level P (Area=0.5) 0.0319
Youden index
Youden index J 0.5500
Associated criterion >15.5
Area under curve -0.702500
Statistical significane p=0.0319
In  our  study  ATONIC  PPH  has significant statistical association
with  maternal serum  Homocysteine  level  of  >15.5µmol/l.
In our study, there is an association  between  maternal  homocysteine
level  and  various  maternal  morbidities in  preeclamptic  mothers. And all
the  maternal  morbidities  occurred  in  mothers  with homocysteine  level  of
more  than 15μ/L.
DISCUSSION
In our study, 60 patients were included after fulfilling the inclusion
and exclusion criteria . 30 patients had    preeclampsia  and 30  patients had
normal pregnancy.
The  average  gestational  age  of  preeclamptic  women   was  36.03
wks  and  normal  Pregnant was  35.70  wks .There  was  no  statistical
difference  in the  gestational age  in both the groups .  In our study, the
mean homocysteine level among normal pregnant mothers was 9.624
μmol/L . This is almost same  as  the  homocysteine  level    8.46 μmol/L in
the study conducted by Mozammel Hoque et al[82]. In another study done
at Canada the mean homocysteine level at 36-42wks among normal
pregnant  women  was  9.5 μmol/L [61] . In the study conducted by Stolkova
et al [86] the  mean  homocysteine  level  was  9.24 μmol/L almost similar to
our study.
In our study , the homocysteine  level  among  the  preeclamptic
women  was  16.92µmol/l. This is close to the study of Hasanzadeh et al
[85] where the homocysteine level was 13.8±7. In another study by Ingec
et al[89] the homocysteine level among preeclamptic women was
16.7±10.1 μmol/L which is almost similar to our study. In our study , there
was a statistically significant difference between the homocysteine level
among normal pregnant women and women with preeclampsia ( p <0.001)
. So our study proves that serum homocysteine is raised in preeclampsia
and there is an association between preeclampsia and
hyperhomocysteinemia . Several studies have proven this concept that
preeclampsia is associated with hyperhomocysteinemia[82-90].
The large Hordaland homocysteine study - a population based study
[97] done over a period of 7 years in a population of about 7,053,
concluded that Hyperhomocysteinemia is a risk factor for preeclampsia.
In the study conducted by Stolkova etal[86] maternal homocysteine
level correlated with the severity of preeclampsia. Our study shows that
maternal homocysteine level is directly associated with the severity of
preeclampsia.
Baksu et al [88] in his study showed that levels differed
significantly among the severe and non severe group. However another
study by Hasanzadeh et al[85] failed to show an association between the
severity of preeclampsia maternal homocysteine level although this study
confirmed hyperhomocysteinemia in preeclampsia[85]. These findings points
that hyperhomocysteinemia due to its direct vascular endothelial injury
and prothrombotic effect on the coagulatory system has a potential role
in the pathogenesis of preeclampsia.
The Hordaland Homocysteine study [97] showed that maternal
hyperhomocysteinemia due to MTHFR 677CT polymorphism is associated
with fetal growth restriction. But  in our study, there was  no association
between maternal hyperhomocysteinemia and fetal growth restriction
(p>0.05).
Studies have shown an association between maternal
hyperhomocysteinemia and abruption [95,97]. On comparing the
homocysteine level, we found that there is significant association between
maternal homocysteine level and morbidities like  Abruption  , Atonic PPH,
DIVC (p<0.05). In our study maternal morbidities occur  with  serum
homocysteine  level   of  more  than  15µmol/l and all these morbidities
occurred only in severe preeclampsia. This is similar to the study of
Baksu et al[88] where a cut-off value of 15μmol/L for maternal
homocysteine level predicted all maternal morbidities. Larger studies are
needed to confirm the level of maternal homocysteine level which can
exactly predict the maternal morbidities. Hyperhomocysteinemia has been
accepted as a cause of placental abruption .[97,98] .
CONCLUSIONS
 Preeclampsia  is  associated  with  Hyperhomocysteinemia.
 In  preeclampsia, homocysteine  levels  are  directly  related  to  the
severity of preeclampsia.
 A  maternal  homocysteine level of  more  than  15μmol/L can  be  used
to  predict  poor  maternal  and  fetal  complications  until  further  larger
studies to  predict the  exact value.
 Hyperhomocysteinemia increases  maternal morbidities  especially
placental abruption, DIVC and Atonic PPH.
LIMITATION OF THE  STUDY

 Sample  size is  small  and  further  studies  with   large  sample  size
have  to be   done to  check  the results.
 Since  nutritional  deficiencies like B12, folate and  B6 are  known to
produce  hyperhomocysteinemia,  better  nutritional  care  to  the  at  risk
mothers  should  be  done  till  further  studies  confirm the role  of
hyperhomocysteinemia  in  preeclampsia.
 Though hyperhomocysteinemia is known to occur in preeclampsia.
the cause for  the  elevation in  preeclampsia  is  still  not known.Further
studies are needed to  know  the  cause  for hyperhomocysteinemia in
preeclampsia which  may  probably  help  in  the pharmacological
management of  pregnant  mothers.
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11 ILAKKIYA 25 36 1 140 90 24.5 15.5 26
12 SRIVIDHYA 26 36 2 180 110 24.5 18.5 22
13 MEENA 27 38 2 150 100 20.5 15.2 30
14 VIOLETMARY 32 35 1 180 120 26.5 18.4 35
15 ANITHA 34 36 1 150 100 24.5 13.5 22
16 PALLAVI 28 37 3 140 90 16.5 15.3 30
17 HAJIRA 26 32 1 180 110 24.5 17.5 26
18 SAROJA 26 38 1 140 90 23.5 13.4 25
19 BHARATHI 26 36 2 170 110 24.5 18.3 116
20 VIJAYA 26 35 1 150 90 23.5 14.2 30
21 DEIVANAI 28 36 3 140 90 24.5 14.3 28
22 ANJALAI 31 35 3 180 120 26.5 20.3 32
23 VEERAMATHI 31 37 3 150 100 25.2 18.4 36
24 PARVATHY 31 37 3 140 90 20.5 12.4 30
25 STELLA 25 35 1 170 120 23.5 19.5 28
26 YAMUNA 25 38 3 180 110 28.5 19.5 30
27 ARULMOZHI 25 37 1 140 90 22.5 13.5 28
28 PARVATHY 26 36 3 160 100 25.3 18.5 32
29 PRIYANKA 26 37 1 170 110 27.5 21.2 35
30 BOOMI 26 38 1 180 120 26.5 18.4 123
31 JANANI 27 38 2 120 80 19.5 12.4 28
32 MANGAI 27 38 2 110 80 18 12.2 20
33 VASANTHI 27 38 2 100 70 20 9.6 18
34 REVATHY 23 36 3 110 70 22.5 10.4 20
35 MURUGAMAL 23 35 3 120 80 19.2 9.5 22
36 MALARKODI 28 37 1 110 70 20.8 9.3 18
37 PRIYA 26 34 2 120 60 19.6 12.4 19
38 SARATHY LAKSHMI 26 36 2 100 60 22.3 9.5 20
39 ILANJIYAM 26 36 2 110 70 22.3 10.2 22
40 CHITRA 22 35 1 100 60 20.2 8.5 19
41 KAVITHA 22 35 3 110 70 20.4 9.5 20
42 KAVERY 29 35 1 100 70 22.3 9.2 18
43 MALIGA 26 37 3 110 70 23.2 9 20
44 KEERTHANA 23 34 2 110 80 19.5 12.4 23
45 KIRUTHIKA 26 35 3 110 80 20.5 7.5 19
46 RAMANI 28 37 2 120 80 21.4 9.4 22
47 ANJUGAM 26 37 2 100 60 20.3 10.5 25
48 PARVATHY 29 36 2 110 60 21.3 9.5 22
49 PRABHA 28 38 1 120 60 20.6 8.5 21
50 FATHIMA 24 36 2 110 70 21.3 7.8 26
51 PARAMESHWARI 25 37 2 120 60 22.3 9.5 26
52 SOWMYA 28 37 2 100 70 21.5 9.4 28
53 JOTHI 29 35 2 110 70 22.5 11.5 23
54 AISHWARYA 26 36 3 120 60 21.5 9.5 22
55 ANU 28 33 2 110 70 22.3 7.6 23
56 ARTHY 27 34 2 100 60 21.5 8.9 24
57 GRACY 28 33 2 110 70 20.5 7.6 26
58 GOMATHI 25 33 1 110 60 21.3 8.2 23
59 KALAVATHY 28 34 2 120 60 20.5 9.5 18
60 MALIGA 26 36 1 100 60 21.5 10.4 19
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1.2 4+ 5.5 7.6 456 1 0 0 0 1 0 0 1 0
0.6 4+ 0.9 7.2 398 1 1 0 0 0 0 1 1 0
0.58 4+ 0.9 7 388 1 0 0 1 0 1 1 0 0
0.8 4+ 1.2 7.5 456 1 1 0 1 0 1 1 0 1
4.5 4+ 0.9 6.5 402 1 1 1 1 0 1 1 1 1
1.2 3+ 1.2 7.5 356 1 0 0 1 0 1 0 1 0
6.5 4+ 1.5 7.5 520 1 1 1 1 0 0 0 1 0
0.9 4+ 0.9 7.2 394 1 0 0 1 0 1 1 1 1
1.4 4+ 1.2 7.5 600 1 0 0 1 0 1 1 0 0
0.8 2+ 0.8 6.5 280 1 0 0 0 0 0 0 1 0
0.7 1+ 0.8 5.6 288 1 0 0 0 0 0 0 0 0
0.9 4+ 0.9 7.5 489 1 0 0 1 0 1 1 0 0
0.8 2+ 0.8 6.5 322 1 0 0 0 0 0 0 1 0
0.8 4+ 4.5 8 556 1 0 0 0 1 0 0 1 0
0.5 2+ 0.8 5.5 356 1 0 0 0 0 0 0 1 0
0.8 2+ 0.7 5.6 256 1 0 0 0 0 0 0 0 0
0.5 3+ 1.8 7 398 1 0 0 1 0 0 0 1 0
0.8 2+ 0.9 6 250 1 0 0 0 0 0 0 0 0
7.5 4+ 1.5 5.5 455 1 0 1 0 0 0 0 1 0
0.7 2+ 0.8 6 278 1 0 0 0 0 0 0 0 0
0.9 2+ 0.5 6 274 1 0 0 0 0 0 0 0 0
0.9 4+ 0.9 7.5 656 1 1 0 1 0 1 0 1 0
0.8 3+ 0.7 6 256 1 0 0 0 0 0 0 1 0
0.8 2+ 1 6 280 1 0 0 0 0 0 0 1 0
0.9 4+ 0.8 7.5 453 1 0 0 0 1 1 0 1 0
0.8 4+ 1.2 8 486 1 0 0 0 0 1 1 0 0
0.8 2+ 0.9 6.8 285 1 0 0 0 0 0 0 1 0
0.9 4+ 0.8 7 455 1 0 0 1 0 0 0 1 0
0.8 4+ 0.9 7.5 390 1 0 0 1 0 1 1 0 0
6.5 4+ 0.9 7 420 1 1 1 0 1 1 1 1 0
0.9 NIL 0.5 5.6 156 0 0 0 0 0 0 0 0 0
0.4 NIL 0.4 5.4 180 0 0 0 0 0 0 0 0 0
0.8 NIL 0.5 5.6 220 0 0 0 0 0 0 0 0 0
0.6 NIL 0.8 5.8 182 0 0 0 0 0 0 0 0 0
0.6 NIL 0.6 5.3 192 0 0 0 0 0 0 0 0 0
0.6 NIL 0.6 5.6 198 0 0 0 0 0 0 0 0 0
0.6 NIL 0.8 5.4 165 0 0 0 0 0 0 0 0 0
0.6 NIL 0.4 4.5 189 0 0 0 0 0 0 0 0 0
0.9 NIL 0.6 5 178 0 0 0 0 0 0 0 0 0
0.5 NIL 0.5 5.6 189 0 0 0 0 0 0 0 0 0
0.5 NIL 0.8 5.4 206 0 0 0 0 0 0 0 0 0
0.5 NIL 0.7 4.6 156 0 0 0 0 0 0 0 0 0
0.9 NIL 0.8 4.9 186 0 0 0 0 0 0 0 0 0
0.6 NIL 0.8 5.2 195 0 0 0 0 0 0 0 0 0
0.8 NIL 0.7 5.6 186 0 0 0 0 0 0 0 0 0
0.5 NIL 0.4 5.9 200 0 0 0 0 0 0 0 0 0
0.8 NIL 0.7 5.6 174 0 0 0 0 0 0 0 0 0
0.6 NIL 0.8 6 185 0 0 0 0 0 0 0 0 0
0.6 NIL 0.9 4.5 145 0 0 0 0 0 0 0 0 0
0.3 NIL 0.6 4.6 196 0 0 0 0 0 0 0 0 0
0.5 NIL 0.8 4.6 203 0 0 0 0 0 0 0 0 0
0.4 NIL 0.7 4.9 203 0 0 0 0 0 0 0 0 0
0.5 NIL 0.5 5.2 185 0 0 0 0 0 0 0 0 0
0.3 NIL 0.5 5.2 200 0 0 0 0 0 0 0 0 0
0.6 NIL 0.9 5.5 186 0 0 0 0 0 0 0 0 0
0.6 NIL 0.5 4.6 186 0 0 0 0 0 0 0 0 0
0.8 NIL 0.6 5.2 189 0 0 0 0 0 0 0 0 0
0.5 NIL 0.8 4.6 178 0 0 0 0 0 0 0 0 0
0.6 NIL 0.4 5.5 186 0 0 0 0 0 0 0 0 0
0.6 NIL 0.9 4.6 198 0 0 0 0 0 0 0 0 0
PROFORMA
NAME
AGE
IP NO
ADDRESS
SOCIOECONOMIC STATUS
OBSTETRICS HISTORY
By dates
1. Obstetrics score Gestational age
By USG
2. Regular ANC
3. LMP EDD
4. Living children
5. Abortion
6. Still birth
7. Previous h/o preeclampsia
COMPLAINTS IF ANY
H/O Headache
H/O Visual disturbances
H/O Epigastric pain
H/O Vomiting
H/O Giddiness
H/O Reduced urine output
H/O Difficulty in breathing
H/O Bleeding p/v
H/O Decreased perception of fetal movements
MENSTRUAL HISTORY :Regular/Irregular
MARIETAL HISTORY :married since
PAST HISTORY
1.Diabetes
2.Hypertension
3.Heart disease
4.Tuberculosis
5.Epilepsy
6.Chronic renal failure
7.Drug intake
GENERAL EXAMINATION
FEBRILE : HEIGHT
PALLOR : WEIGHT
PEDAL EDEMA : BMI
VITALS :
TEMP :
PULSE :
BP:
CVS :
RS:
PER ABDOMEN :
Uterus size:
Uterus acting: yes /no Tense/tenderness:
Fetal position: FH:
Others:
P/V:
INVESTIGATIONS:
COMPLETE HEMOGRAM:
Hb: TC:   DC:      Platrelet:
ESR: Hematocrit:
FBS: PPBS:
BLOOD UREA: Serum creatinine:
Serum uric acid: serum fibrinogen:
LFT:
Total bilirubin: ALT:
SAP: Total protein:
URINE:
Albumin sugar
24 hr urinary protein:
Urine culture with colony count:
Peripheral smear study:
Fundus examination :
SERUM HOMOCYSTEINE:
USG:
CTG:
DIAGNOSIS:
MATERNAL MORBIDITIES: YES/ NO , if yes:
MATERNAL MORTALITY :




